- Home
- QIPT vs STRO Comparison
QIPT vs STRO Comparison
Compare QIPT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QIPT | STRO |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.7M | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | QIPT | STRO |
|---|---|---|
| Price | $3.56 | $11.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | $3.83 | ★ $18.29 |
| AVG Volume (30 Days) | ★ 1.2M | 105.4K |
| Earning Date | 02-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,359,000.00 | $105,646,000.00 |
| Revenue This Year | $28.30 | $63.08 |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $5.23 |
| 52 Week High | $3.55 | $21.50 |
Technical Indicators
Market Signals| Indicator | QIPT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 85.17 | 73.40 |
| Support Level | $3.52 | $10.15 |
| Resistance Level | $3.54 | $12.18 |
| Average True Range (ATR) | 0.02 | 0.88 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 87.50 | 77.27 |
Price Performance
Historical ComparisonAbout QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.